{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:16:29Z","timestamp":1787948189523,"version":"build-2784847793"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30DK026743"],"award-info":[{"award-number":["P30DK026743"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K24AA022523"],"award-info":[{"award-number":["K24AA022523"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"DOI":"10.1007\/s10620-026-10215-1","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T19:25:13Z","timestamp":1787945113000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal Adherence to Hepatocellular Carcinoma Surveillance and Associated Outcomes Following Ultrasound Liver Imaging Reporting and Data System (US LI-RADS) Implementation"],"prefix":"10.1007","author":[{"given":"Stephanie M.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailey H.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy M.","family":"Shui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Finke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rena K.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9178-9139","authenticated-orcid":false,"given":"Mandana","family":"Khalili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"10215_CR1","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723\u2013750.","journal-title":"Hepatology."},{"key":"10215_CR2","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.cgh.2018.05.039","volume":"17","author":"NE Rich","year":"2019","unstructured":"Rich NE, Hester C, Odewole M, Murphy CC, Parikh ND, Marrero JA et al. Racial and ethnic differences in presentation and outcomes of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2019;17:551-559.e1.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10215_CR3","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.jamcollsurg.2016.12.023","volume":"224","author":"RS Hoehn","year":"2017","unstructured":"Hoehn RS, Hanseman DJ, Dhar VK, Go DE, Edwards MJ, Shah SA. Opportunities to improve care of hepatocellular carcinoma in vulnerable patient populations. J Am Coll Surg. 2017;224:697\u2013704.","journal-title":"J Am Coll Surg."},{"key":"10215_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1158\/1055-9965.EPI-24-1094","volume":"34","author":"S Patel","year":"2025","unstructured":"Patel S, Khalili M, Singal AG, Pinheiro PS, Jones PD, Kim RG et al. Significant disparities in hepatocellular carcinoma outcomes by race\/ethnicity and sociodemographic factors. Cancer Epidemiol Biomarkers Prev. 2025;34:355\u2013365.","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"10215_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2147\/JHC.S186239","volume":"5","author":"KM Elsayes","year":"2019","unstructured":"Elsayes KM, Kielar AZ, Chernyak V, Morshid A, Furlan A, Masch WR et al. LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance. J Hepatocell Carcinoma. 2019;5:49\u201369.","journal-title":"J Hepatocell Carcinoma."},{"key":"10215_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.20517\/2394-5079.2021.131","volume":"8","author":"JC Ahn","year":"2022","unstructured":"Ahn JC, Lee YT, Agopian VG, Zhu Y, You S, Tseng HR, Yang JD. Hepatocellular carcinoma surveillance: current practice and future directions. Hepatoma Res. 2022;8:10. https:\/\/doi.org\/10.20517\/2394-5079.2021.131.","journal-title":"Hepatoma Res."},{"key":"10215_CR7","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/hep.23615","volume":"52","author":"JA Davila","year":"2010","unstructured":"Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, El-Serag HB. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology. 2010;52:132\u2013141.","journal-title":"Hepatology."},{"key":"10215_CR8","doi-asserted-by":"publisher","first-page":"e30538","DOI":"10.1097\/MD.0000000000030538","volume":"101","author":"T Teerasarntipan","year":"2022","unstructured":"Teerasarntipan T, Sritunyarat Y, Prathyajuta P, Pitakkitnukun P, Phathong C, Ariyaskul D et al. Physician- and patient-reported barriers to hepatocellular carcinoma surveillance: a nationwide survey. Medicine (Baltimore). 2022;101:e30538.","journal-title":"Medicine (Baltimore)."},{"key":"10215_CR9","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1002\/jmri.26027","volume":"47","author":"AZ Kielar","year":"2018","unstructured":"Kielar AZ, Chernyak V, Bashir MR, Do RK, Fowler KJ, Mitchell DG et al. LI-RADS 2017: an update. J Magn Reson Imaging. 2018;47:1459\u20131474.","journal-title":"J Magn Reson Imaging."},{"key":"10215_CR10","doi-asserted-by":"publisher","first-page":"e230118","DOI":"10.1148\/rycan.230118","volume":"6","author":"HH Choi","year":"2024","unstructured":"Choi HH, Kim S, Shum DJ, Huang CY, Shui A, Fox RK, Khalili M. Assessing adherence to US LI-RADS follow-up recommendations in vulnerable patients undergoing hepatocellular carcinoma surveillance. Radiol Imaging Cancer. 2024;6:e230118.","journal-title":"Radiol Imaging Cancer."},{"key":"10215_CR11","doi-asserted-by":"publisher","first-page":"e000192","DOI":"10.1136\/bmjgast-2017-000192","volume":"5","author":"SA Tran","year":"2018","unstructured":"Tran SA, Le A, Zhao C, Hoang J, Yasukawa LA, Weber S et al. Rate of hepatocellular carcinoma surveillance remains low for a large, real-life cohort of patients with hepatitis C cirrhosis. BMJ Open Gastroenterol. 2018;5:e000192.","journal-title":"BMJ Open Gastroenterol."},{"key":"10215_CR12","doi-asserted-by":"publisher","first-page":"e4744","DOI":"10.1097\/MD.0000000000004744","volume":"95","author":"C Wang","year":"2016","unstructured":"Wang C, Chen V, Vu V, Le A, Nguyen L, Zhao C et al. Poor adherence and low persistency rates for hepatocellular carcinoma surveillance in patients with chronic hepatitis B. Medicine (Baltimore). 2016;95:e4744.","journal-title":"Medicine (Baltimore)."},{"key":"10215_CR13","doi-asserted-by":"publisher","first-page":"68131","DOI":"10.18632\/oncotarget.19245","volume":"8","author":"P Liu","year":"2017","unstructured":"Liu P, Xie SH, Hu S, Cheng X, Gao T, Zhang C, Song Z. Age-specific sex difference in the incidence of hepatocellular carcinoma in the United States. Oncotarget. 2017;8:68131\u201368137.","journal-title":"Oncotarget."},{"key":"10215_CR14","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1158\/1940-6207.CAPR-12-0046","volume":"5","author":"AG Singal","year":"2012","unstructured":"Singal AG, Yopp AC, Gupta S, Skinner CS, Halm EA, Okolo E et al. Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prev Res (Phila). 2012;5:1124\u20131130.","journal-title":"Cancer Prev Res (Phila)."},{"key":"10215_CR15","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1513\/AnnalsATS.202006-631RL","volume":"18","author":"M Triplette","year":"2021","unstructured":"Triplette M, Thayer JH, Kross EK, Cole AM, Wenger D, Farjah F et al. The impact of smoking and screening results on adherence to follow-up in an academic multisite lung cancer screening program. Ann Am Thorac Soc. 2021;18:545\u2013547.","journal-title":"Ann Am Thorac Soc."},{"key":"10215_CR16","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1002\/hep.31554","volume":"73","author":"AS Lok","year":"2021","unstructured":"Lok AS, Perrillo R, Lalama CM, Fried MW, Belle SH, Ghany MG et al. Hepatology. 2021;73:2124\u20132140.","journal-title":"Hepatology."},{"key":"10215_CR17","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1097\/HEP.0000000000000389","volume":"78","author":"SL Friedman","year":"2023","unstructured":"Friedman SL, Sanyal AJ. The future of hepatology. Hepatology. 2023;78:637\u2013648.","journal-title":"Hepatology."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-10215-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-026-10215-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-10215-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T19:25:14Z","timestamp":1787945114000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-026-10215-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":17,"alternative-id":["10215"],"URL":"https:\/\/doi.org\/10.1007\/s10620-026-10215-1","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"assertion":[{"value":"7 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Mandana Khalili is a recipient of research grants (to her institution) from Gilead Sciences and Intercept Pharmaceuticals, and she has served as a consultant for Gilead Sciences, GSK Pharmaceuticals and Resolution Therapeutics. Rena Fox is a recipient of research grants (to her institution) from Gilead Sciences, Inc., Petauri Kinect, and Novo Nordisk, Inc. and she has served as a consultant for Novo Nordisk, Inc. and Boehringer Ingelheim, Inc. All other authors have no relevant disclosures.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}